Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: Markers of vulnerability or disease?

Biological Psychiatry

Volumn 40, Issue 9, 1996, Pages 825-833

  Zorrilla, Eric P ^a   Cannon, Tyrone D ^a   Gur, Raquel E ^a   Kessler, Jason ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoantibodies; Family study; Granulocytes; Leukocytes; Lymphocytes; Monocytes

Indexed keywords

AUTOANTIBODY; MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; FAMILY; FEMALE; GRANULOCYTOSIS; HUMAN; IMMUNOLOGY; LEUKOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030298025     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00598-6     Document Type: Article

References (70)

1. Achiron A, Noy S, Pras E, Lereya J, Hermesh H, Laor N (1994): T-cell subsets in acute psychotic schizophrenic patients. Biol Psychiatry 35:27-31.
2. Asano S, Okano A, Ozawa K, et al (1990): In vivo effects of human interleukin-6 in primates: Stimulated production of platelets. Blood 75:1602-1605.
3. Bach JF (1994): Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 15:516-542.
4. Caldwell CL, Irwin M, Lohr J (1991): Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 30:1131-1138.
5. Cannon TD, Marco E (1994): Structural brain abnormalities as indicators of vulnerability to schizophrenia. Schizophr Bull 20:89-102.
6. Cannon TD, Eyler Zorrilla L, Shtasel D, et al (1994): Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 51:651-661.
7. Canoso RT, de Oliveira RM (1986): Characterization and antigenic specificity of chlorpromazine-induced antinuclear antibodies. J Lab Clin Med 108:213-216.
8. Canoso RT, Sise HS (1982): Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 13:121-129.
9. Canoso RT, de Oliveira RM, Nixon RA (1990): Neuroleptic-associated autoantibodies: A prevalence study. Biol Psychiatry 27:863-870.
10. Chengappa KN, Carpenter AB, Keshavan MS, et al (1991): Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 30:731-735.
11. Coffey CE, Sullivan JL, Rice JR (1983): T lymphocytes in schizophrenia. Biol Psychiatry 18:113-119.
12. Dameshek W (1930): The white blood cells in dementia praecox and dementia paralytica. Arch Neurol Psychiatry 24:855.
13. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM (1995): Schizophrenia and smoking: An epidemiological survey in a state hospital. Am J Psychiatry 152:453-455.
14. DeLisi LE, Wyatt RJ (1982): Abnormal immune regulation in schizophrenic patients. Psychopharmacol Bull 18:158-163.
15. DeLisi LE, Goodman S, Neckers LM, Wyatt RJ (1982): An analysis of lymphocyte subpopulations in schizophrenic patients. Biol Psychiatry 17:1003-1009.
16. DeLisi LE, Goldin LR, Gershon ES (1987): Studies of biological factors associated with the inheritance of schizophrenia: A selective review. J Psychiatr Res 21:507-513.
17. Diebold K (1976): Leukocyte count in manics, endogenous depressives, schizophrenics and neurotics. Psychiatria Clinica 9:230-235.
18. Eyler Zorrilla LT, Cannon TD (1995): Structural brain abnormalities in schizophrenia: Distribution, etiology, and implications. In Mednick S (ed), Neural Development in Schizophrenia: Theory and Research. New York: Plenum Press, pp 57-69.
19. Fessel WJ (1961): Disturbed serum proteins in chronic psychosis. Arch Gen Psychiatry 4:154-159.
20. Fishman P, Sredni P, Djaldetti M (1990): Recent advances in interleukin-3 research: A review. Isr J Med Sci 26:414-419.
21. Ganguli R, Rabin BS (1993): Cd5 positive b-lymphocytes in schizophrenia: No alteration in numbers or percentage as compared with control subjects. Psychiatry Res 48:69-78.
22. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS (1992a): Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production. Psychiatry Res 44:113-123.
23. Ganguli R, Rabin BS, Brar JS (1992b): Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol Psychiatry 32:735-738.
24. Ganguli R, Brar JS, Chengappa KNR, Yang ZW, Nimgaonkar VL, Rabin BS (1993): Autoimmunity in schizophrenia: A review of recent findings. Ann Med 25:489-496.
25. Ganguli R, Yang Z, Shurin G, et al (1994): Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Res 51:1-10.
26. Gottfries CG, Gottfries I (1974): Antinuclear factors in relation to age, sex, mental disease and treatment with phenothiazines. Acta Psychiatr Scand 255(suppl):193-201.
27. Harley JB, Sheldon P, Neas B, et al (1994): Systemic lupus erythematosus: Considerations for a genetic approach. J Invest Dermatol 103:144S-149S.
28. Herbert TB, Cohen S (1993): Depression and immunity: A meta-analytic review. Psychol Bull 113:472-486.
29. Hirata-Hibi M, Hayashi K (1993): The anatomy of the P-lymphocyte. Schizophr Res 8:257-262.
30. Irwin M, Segal DS, Hauger RL, Smith TL (1989): Individual behavioral and neuroendocrine differences in responsiveness to audiogenic stress. Pharmacol Biochem Behav 32:913-917.
31. Johnstone E, Whaley K (1975): Antinuclear antibodies in psychiatric illness: Their relationship to diagnosis and drug treatment. Br Med J 2:724-725.
32. Katila H, Appelberg B, Hurme M, Rimon R (1994): Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12:29-34.
33. Kronfol Z, House JD (1989): Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 80:142-147.
34. Kronfol Z, Turner R, Nasrallah H, Winokur G (1984): Leukocyte regulation in depression and schizophrenia. Psychiatry Res 13:13-18.
35. Kronfol Z, Turner R, House JD, Winokur G (1986): Elevated blood neutrophil concentration in mania. J Clin Psychiatry 47:63-65.
36. Lohr JB, Flynn K (1992): Smoking and schizophrenia. Schizophr Res 8:93-102.
37. Loranger AW, Susman VL, Oldham JM, Russakoff LM (1987): The Personality Disorder Examination: A preliminary report. J Personality Disord 1:1-13.
38. Maes M, Van der Planken M, Stevens WJ, et al (1992): Leukocytosis, monocytosis and neutrophilia: Hallmarks of severe depression. J Psychiat Res 26:125-134.
39. Macs M, Meltzer HY, Bosmans E (1994a): Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346-351.
40. Macs M, Stevens W, Scharpe S, et al (1994b): Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6 and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia 50:821-829.
41. Masserini C, Vita A, Basile R, et al (1990): Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables. Schizophr Res 3:269-275.
42. Milhorat AT, Small SM, Diethelm O (1942): Leukocytosis during various emotional states. Arch Neurol Psychiatry 47:779.
43. Moreland LW, Koopman WJ (1991): Infection as a cause of arthritis. Curr Opin Rheumatol 3:639-649.
44. Nyland H, Naess A, Lunde H (1980): Lymphocyte subpopulations in peripheral blood from schizophrenic patients. Acta Psychiatr Scand 61:313-318.
45. Osgood EE, Brownlee IE, Osgood MW, Ellis DM, Cohen W (1939): Total, differential and absolute leukocyte counts and sedimentation rates determined for healthy persons nineteen years of age and over. Arch Int Med 64:105.
46. Panitch HS (1994): Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(suppl):S25-S28.
47. Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM (1993): Increased serum-soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci 243:7-10.
48. Reveley AM, Reveley MA, Clifford CA, Murray RM (1982): Cerebral ventricular size in twins discordant for schizophrenia. Lancet i: 540-541.
49. Sasaki I, Nanko S, Fukuda R, Kawate T, Kunugi H, Kazamatsuri H (1994): Changes of immunological functions after acute exacerbation in schizophrenia. Biol Psychiatry 35:173-178.
50. SAS Institute (1988): SAS/STAT User's Guide. Cary, NC: Author.
51. Shintani F, Kanba S, Maruo N, et al (1991): Serum interleukin-6 in schizophrenic patients. Life Sci 49:661-664.
52. Shtasel DL, Gur RE, Mozley PD, et al (1991): Volunteers for biomedical research. Recruitment and screening of normal controls. Arch Gen Psych 48:1022-1025.
53. Sirota P, Firer M, Schildi K, et al (1993a): Increased anti-Sm antibodies in schizophrenic patients and their families. Prog Neuro Psychopharmacol Biol Psychiatry 17:793-800.
54. Sirota P, Firer MA, Schild K, et al (1993b): Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 33:450-455.
55. Sirota P, Schild K, Elizur A, Dialdetti M, Fishman P (1995): Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuro Psychopharmacol 19:75-83.
56. Spitzer RL, Williams JB, Gibbon M (1987a): Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID). New York: Biometrics Research Department, New York State Psychiatric Institute.
57. Spitzer RL, Williams JB, Gibbons M, First MB (1987b): Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). New York: Biometrics Research Department, New York State Psychiatric Institute.
58. Spring BJ, Zubin J (1978): Attention and information processing as indicators of vulnerability to schizophrenic episodes. In Wynne LC, Cromwell RL, Matthysse S (eds), The Nature of Schizophrenia: Approaches to Research and Treatment. New York: Wiley, pp 366-375.
59. Tsuang MT, Lyons MJ, Faraone SV (1990): Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry 156:17-26.
60. Ulich TR, del Castillo J, Busser K, Guo KZ, Yin SM (1989a): Acute in vivo effects of IL-3 alone and in combination with IL-6 on the blood cells of the circulation and bone marrow. Am J Pathol 135:663-670.
61. Ulich TR, del Castillo J, Guo K (1989b): In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBC's and WBC's. Blood 73:108-110.
62. Ulich TR, Guo KZ, Remick D, del Castillo J, Yin S (1991): Endotoxin-induced cytokine gene expression in vivo: III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. Immunol 146:2316-2323.
63. Villemain F, Magnin M, Feuillet FMN, Zarifian E, Loo H, Bach JF (1988): Anti-histone antibodies in schizophrenia and affective disorders. Psychiatry Res 24:53-60.
64. Villemain F, Chatenoud L, Galinowski A, et al (1989): Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production. Am J Psychiatry 146:609-616.
65. von Brauchitsch H (1972): Antinuclear factor in psychiatric disorders. Am J Psychiatry 128:1552-1554.
66. Weinberger DR, DeLisi LE, Neophytides AN, Wyatt RJ (1981): Familial aspects of CT scan abnormalities in chronic schizophrenic patients. Psychiatry Res 4:65-71.
67. Winokur G, Tsuang M (1981): Paranoid versus nonparanoid schizophrenia: Definition and association. In Perris C, Struwe G, Jannson G (eds), Proceedings, Third World Congress of Biological Psychiatry. Amsterdam: Elsevier/North-Holland.
68. Xu HM, Wei J, Hemmings GP (1994): Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 164:251-253.
69. Yannitsi SG, Manoussakis MN, Mavridis AK, et al (1990): Factors related to the presence of autoantibodies in patients with chronic mental disorders. Biol Psychiatry 27:747-756.
70. Zarrabi MH, Zucker S, Miller F, et al (1979): Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Int Med 91:194-199.